All In Biotech

Drug Trial Radar · NCT05590260

Prevention of Iron Deficiency Anemia Post-delivery

Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,857 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,857

Actual

Start

May 30, 2023

Primary completion

Mar 10, 2025

Study completion Jul 28, 2025

Sponsor

Sponsor type
Research network
Collaborators
Thomas Jefferson University; University of North Carolina, Chapel Hill; Kinshasa School of Public Health; University of Alabama at Birmingham; University Teaching Hospital, Lusaka, Zambia; University of Colorado, Denver; Institute of Nutrition of Central America and Panama; University of Virginia; International Centre for Diarrhoeal Disease Research, Bangladesh; Columbia University; Aga Khan University; Boston University; Lata Medical Research Foundation, Nagpur; Indiana University; Moi University; RTI International; Bill and Melinda Gates Foundation; KLE University Jawaharlal Nehru Medical College
First posted
Oct 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 15 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRIORITY is designed as a 2-arm, randomized-controlled trial focused on postpartum women. The trial will recruit women who are diagnosed with moderate anemia based on a blood sample taken 6-48 hours after childbirth. A total of 4,800 eligible women, or 600 women per research site, will be consented and enrolled in the trial. The study hypothesizes that at 6 weeks postpartum, the incidence of achieving a non-anemic state (defined as Hb ≥11 g/dL) will be greater among women receiving a single-dose infusion of IV iron than among women receiving standard care with oral iron.

Conditions

  • Postpartum Anemia

Interventions

  • Ferric carboxymaltose (FCM) and folic acid tabletsDrug

    FCM 50 mg iron/mL will be in a solution of 20 mL vials for infusion, using a dosage of 20 mg elemental iron per kg body weight, up to a maximum of 1 g, in a single IV infusion over 20-30 minutes. 400 mcg of folic acid daily to 6 months.

  • Oral iron tablets and folic acid tabletsDrug

    60 mg elemental iron twice daily to 6-weeks with then once or twice daily (based on Hb at 6-weeks) to 6-months. 400 mcg of folic acid daily to 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maternal non-anemic state (Hb ≥11 g/dL)Time frame: 6 weeks post-delivery

Locations

8 sites in 7 countries. Site status is shown where the registry gives one.

  • ICDDRB

    Dhaka, Bangladesh

  • Kinshasa School of Public Health

    Kinshasa, Democratic Republic of the Congo

  • INCAP

    Guatemala City, Guatemala

  • Lata Medical Research Foundation

    Nagpur, India, India

  • KLE Society's Jawaharlal Nehru Medical College

    Belagavi, Karnataka, India

  • Moi University School of Medicine

    Eldoret, Kenya

  • The Aga Khan University

    Karachi, Pakistan, Pakistan

  • University Teaching Hospital

    Lusaka, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.